Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 7/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 3/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL8741640 | 0.93 | LMNA (0.40) | KIF11LMNACYP1A2AGTR1HTT | |
| SCHEMBL1263157 | 0.88 | KIF11 (0.41) | KIF11LMNACYP1A2AGTR1HTT | |
| SCHEMBL9453914 | 0.85 | CYP1A2 (0.54) | LMNACYP1A2AGTR1HTTNR3C2 | |
| SCHEMBL2561548 | 0.83 | KIF11 (0.46) | KIF11 | |
| SCHEMBL2897015 | 0.81 | KIF11 (0.61) | KIF11 | |
| SCHEMBL26068376 | 0.81 | KIF11 (0.61) | KIF11 | |
| SCHEMBL1263156 | 0.81 | KIF11 (0.61) | KIF11 | |
| SCHEMBL992027 | 0.79 | KIF11 (0.42) | KIF11LMNAHTTNR3C2POLB | |
| SCHEMBL2368140 | 0.78 | LMNA (0.38) | LMNACYP1A2AGTR1HTTNR3C2 | |
| SCHEMBL7912698 | 0.78 | KIF11 (0.45) | KIF11LMNACYP1A2AGTR1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1913011-B1 | OLIGONUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS INC (US) | 2016-11-02 | — | — | EP | disclosed |
| EP-3034510-A1 | OLIGONUCLEOTIDES COMPRISING A C5-MODIFIED PYRIMIDINE | Alnylam Pharmaceuticals Inc. (US) | 2016-06-22 | — | — | EP | disclosed |
| EP-1337547-B1 | NUCLEASE-BASED METHOD FOR DETECTING AND QUANTITATING OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS INC (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-1789553-B1 | OLIGONUCLEOTIDES COMPRISING A NON-PHOSPHATE BACKBONE LINKAGE | ALNYLAM PHARMACEUTICALS INC (US) | 2014-03-26 | — | — | EP | disclosed |
| US-8470988-B2 | Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety | ALNYLAM PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-8163477-B2 | Detecting antisense oligonucleotides 20 to 30 nucleobases in length in a bodily fluid or extract; colorimetric analysis | ISIS PHARMACEUTICALS, INC (US) | 2012-04-24 | — | — | US | disclosed |
| US-20110250138-A1 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A METAL-CHELATING LIGAND | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-13 | — | — | US | disclosed |
| US-8013136-B2 | Oligonucleotides comprising a non-phosphate backbone linkage | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-7893224-B2 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100197899-A1 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A 2-ARYLPROPYL MOIETY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-08-05 | — | — | US | disclosed |
| US-20020049163-A1 | Nucleosidic and non-nucleosidic folate conjugates | ISIS PHARMACEUTICALS, INC. | 2002-04-25 | — | — | US | disclosed |
| EP-1185305-A1 | LIGAND-CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2002-03-13 | — | — | EP | disclosed |
| EP-1186613-A1 | New reagent for labelling nucleic acids | Roche Diagnostics GmbH (DE) | 2002-03-13 | — | — | EP | disclosed |
| US-6355438-B1 | DETECTING AND COUNTING PREFERENTIAL NUCLEIC ACIDS IN SAMPLE; OBTAIN SAMPLE, INCUBATE WITH PROBES, INCUBATE HYBRID WITH PREFERENTIAL ENZYMES, DETECT LABEL, PRESENCE OF LABEL INDICATES PRESENCE OF TARGET NUCLEOTIDE SEQUENCES | ISIS PHARMACEUTICALS, INC. | 2002-03-12 | — | — | US | disclosed |
| US-6335434-B1 | FOR INCREASED MEMBRANE PERMEABILITY OF OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC., | 2002-01-01 | — | — | US | disclosed |
| WO-2001034845-A1 | METHOD FOR QUANTITATING OLIGONUCLEOTIDES | ISIS PHARMACEUTICALS, INC. (US) | 2001-05-17 | — | — | WO | disclosed |
| US-6232296-B1 | ADMINISTERING OLIGONUCLEOTIDE WITH ONE OR MORE PHOSPHOROTHIOATE MODIFICATIONS | ISIS PHARMACEUTICALS, INC. | 2001-05-15 | — | — | US | disclosed |
| WO-2000076554-A1 | LIGAND-CONJUGATED OLIGOMERIC COMPOUNDS | ISIS PHARMACEUTICALS, INC. (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-1999066063-A9 | NUCLEOSIDIC AND NON-NUCLEOSIDIC FOLATE CONJUGATES | ISIS PHARMACEUTICALS INC (US) | 2000-06-08 | — | — | WO | disclosed |
| WO-1999066063-A2 | NUCLEOSIDIC AND NON-NUCLEOSIDIC FOLATE CONJUGATES | ISIS PHARMACEUTICALS, INC. (US) | 1999-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049163-A1 | Nucleosidic and non-nucleosidic folate conjugates | MTHFD1, DHFR, FOLR1 | KIF11 1644/4885LMNA 1625/4885CYP1A2 3392/4885 |
| US-20100197899-A1 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A 2-ARYLPROPYL MOIETY | SAAL1, OPRL1, ANXA2 | KIF11 4394/4885LMNA 2623/4885CYP1A2 93/4885 |
| US-20110250138-A1 | SINGLE-STRANDED AND DOUBLE-STRANDED OLIGONUCLEOTIDES COMPRISING A METAL-CHELATING LIGAND | SLC40A1, SLCO1B1, SLCO2A1 | KIF11 2771/4885LMNA 2168/4885CYP1A2 4524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.